NMTR vs. PTEIQ, BBLG, EVLO, EVFM, VRAX, SBFM, SPRC, LSDI, HSTO, and AFIB
Should you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include PolarityTE (PTEIQ), Bone Biologics (BBLG), Evelo Biosciences (EVLO), Evofem Biosciences (EVFM), Virax Biolabs Group (VRAX), Sunshine Biopharma (SBFM), SciSparc (SPRC), Lucy Scientific Discovery (LSDI), Histogen (HSTO), and Acutus Medical (AFIB). These companies are all part of the "medical" sector.
9 Meters Biopharma (NASDAQ:NMTR) and PolarityTE (NASDAQ:PTEIQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
PolarityTE has higher revenue and earnings than 9 Meters Biopharma. PolarityTE is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.
9 Meters Biopharma received 37 more outperform votes than PolarityTE when rated by MarketBeat users.
PolarityTE's return on equity of -106.08% beat 9 Meters Biopharma's return on equity.
9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, PolarityTE has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 11.8% of PolarityTE shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 5.4% of PolarityTE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled PolarityTE'saverage media sentiment score.
9 Meters Biopharma presently has a consensus target price of $1.70, suggesting a potential upside of ∞. Given 9 Meters Biopharma's higher possible upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than PolarityTE.
Summary
PolarityTE beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks.
Get 9 Meters Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
9 Meters Biopharma Competitors List
Related Companies and Tools